At a glance
| Identity | Synthetic native GnRH; 10 amino acids |
|---|---|
| Target | Pituitary GnRH receptor |
| Pattern matters | Pulsatile stimulation differs from continuous exposure |
| Historical human brands | Factrel and Lutrepulse Kit |
| Current US records | Historical products listed discontinued |
| Compounded status | Not FDA-approved |
Overview
Gonadorelin reproduces the native ten-amino-acid hypothalamic hormone rather than a long-acting GnRH analogue. Pulsatile delivery has been studied for selected patients whose reproductive hormone deficiency originates in the hypothalamus, provided pituitary and gonadal function can respond. Historical US products included Factrel and Lutrepulse Kit; FDA product records list both applications’ products as discontinued. A compounded preparation does not inherit those products’ approval or establish equivalence to a study’s drug and delivery system. Veterinary gonadorelin products are separate medicines and are not evidence of current approval for human treatment.
How it works
GnRH binds receptors on pituitary gonadotroph cells and stimulates LH and FSH secretion. The timing of stimulation is central: physiological pulses sustain gonadotropin output, while prolonged continuous stimulation can desensitize the pathway. Consequently, results from a pulsatile delivery system cannot be assumed for an unrelated intermittent regimen. Response also depends on the site of the underlying defect; a damaged pituitary or gonad may not respond normally.
What does the human fertility evidence show?
A clinical study treated 11 men with idiopathic hypogonadotropic hypogonadism using prolonged pulsatile GnRH. Eight developed spermatogenesis on GnRH alone, with another responding after additional gonadotropin treatment. The selected population and specialized delivery method limit extrapolation to other causes of infertility or unrelated hormone regimens.
Supporting sources [1]
What happened to the historical US medicines?
FDA records for Factrel, application 018123, and Lutrepulse Kit, application 019687, list their human products as discontinued. These records document past approved products, not approval of a new compounded preparation. The fact that an active ingredient has a regulatory history does not approve every formulation containing it.
What remains uncertain with compounded preparations?
Compounded medicines do not undergo FDA premarket verification of safety, effectiveness and quality. Concentration errors, contamination and product consistency are relevant concerns. For gonadorelin, clinical response also requires the correct diagnosis and delivery pattern; a hormone increase alone does not confirm successful spermatogenesis or pregnancy benefit.
Does pulsatile GnRH evidence prove fertility preservation during testosterone therapy?
No. Research in men with hypothalamic hormone deficiency is not the same clinical question as adding a compounded product to testosterone treatment. The evidence cited here does not establish that an arbitrary intermittent regimen preserves fertility. Both the underlying diagnosis and the actual treatment method must match the supporting evidence.
Reading this profile
Jurisdiction: United States: historical human gonadorelin products are listed discontinued; compounded preparations are not FDA-approved.. Molecular class: Synthetic form of the native decapeptide gonadotropin-releasing hormone.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Pulsatile gonadotropin-releasing hormone treatment of men with idiopathic hypogonadotropic hypogonadism. ↗Original research · Checked 2026-10-27
- FDA Drugs@FDA — Factrel, NDA 018123 ↗Regulatory source · Checked 2026-10-27
- FDA Drugs@FDA — Lutrepulse Kit, NDA 019687 ↗Regulatory source · Checked 2026-10-27
- FDA — compounding questions and answers ↗Regulatory source · Checked 2026-10-27